Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality
This large-scale database study revealed that treatment for OAB is often initiated with β<sub>3</sub>A and prescribed mainly at clinics. Changes or additions to initial prescriptions were as low as about 5%, indicating that raising awareness among physicians treating OAB is particularly important to improve the quality of life of patients with OAB. Our study also showed that the incidence of AEs was not associated with the initially prescribed drug type. Continued exploration is warranted to further clarify the risk of AEs with each prescription.
Authors
- Masashi Mikami (ORCID: https://orcid.org/0000-0001-7731-847X)
- Yu Okabe (ORCID: https://orcid.org/0009-0008-9669-6896)
- Hiroshi Matsuzaki (ORCID: https://orcid.org/0000-0001-5615-2140)
- Taiki Emoto
- Naotaka Gunge
- Chizuru Nakagawa
- Takahiro Kitano
- Chikao Aoyagi (ORCID: https://orcid.org/0000-0001-6625-5127)
- Yuichiro Fukuhara
- Kazuna Tsubouchi (ORCID: https://orcid.org/0000-0002-4286-3942)
- Nobuhiro Haga (ORCID: https://orcid.org/0000-0003-3618-5214)
- Hiroshi Nakazawa (ORCID: https://orcid.org/0000-0001-6408-6163)
- Hisatomi Arima (ORCID: https://orcid.org/0000-0002-2064-2014)
- Nobuyuki Nakamura (ORCID: https://orcid.org/0000-0003-4874-6963)
- Takeshi Miyazaki (ORCID: https://orcid.org/0000-0002-9212-7396)
- Masahiro Tachibana
- Fumihiro Yamazaki
- Kosuke Tominaga
Institutions
- Fukuoka University (JP)
- Pfizer (Japan) (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1007/s12325-024-03070-x
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer Japan